Charles A Baker - Net Worth and Insider Trading
Charles A Baker Net Worth
The estimated net worth of Charles A Baker is at least $7 Million dollars as of 2024-11-13. Charles A Baker is the Director of Regeneron Pharmaceuticals Inc and owns about 9,000 shares of Regeneron Pharmaceuticals Inc (REGN) stock worth over $7 Million. Details can be seen in Charles A Baker's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Charles A Baker has not made any transactions after 2017-09-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Charles A Baker
Charles A Baker Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Charles A Baker owns 2 companies in total, including Regeneron Pharmaceuticals Inc (REGN) , and Progenics Pharmaceuticals Inc (PGNX) .
Click here to see the complete history of Charles A Baker’s form 4 insider trades.
Insider Ownership Summary of Charles A Baker
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc | 2017-09-29 | director |
| PGNX | Progenics Pharmaceuticals Inc | 2012-06-13 | director |
Charles A Baker Latest Holdings Summary
Charles A Baker currently owns a total of 1 stock. Charles A Baker owns 9,000 shares of Regeneron Pharmaceuticals Inc (REGN) as of September 29, 2017, with a value of $7 Million.
Latest Holdings of Charles A Baker
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc | 2017-09-29 | 9,000 | 821.00 | 7,389,000 |
Holding Weightings of Charles A Baker
Charles A Baker Form 4 Trading Tracker
According to the SEC Form 4 filings, Charles A Baker has made a total of 0 transactions in Regeneron Pharmaceuticals Inc (REGN) over the past 5 years. The most-recent trade in Regeneron Pharmaceuticals Inc is the sale of 2,000 shares on September 29, 2017, which brought Charles A Baker around $900,000.
Insider Trading History of Charles A Baker
- 1
Charles A Baker Trading Performance
Charles A Baker Ownership Network
Ownership Network List of Charles A Baker
Ownership Network Relation of Charles A Baker
Charles A Baker Owned Company Details
What does Regeneron Pharmaceuticals Inc do?
Who are the key executives at Regeneron Pharmaceuticals Inc?
Charles A Baker is the director of Regeneron Pharmaceuticals Inc. Other key executives at Regeneron Pharmaceuticals Inc include SVP Commercial Marion Mccourt , VP & Controller Christopher R. Fenimore , and EVP Research Andrew J Murphy .
Regeneron Pharmaceuticals Inc (REGN) Insider Trades Summary
Over the past 18 months, Charles A Baker made no insider transaction in Regeneron Pharmaceuticals Inc (REGN). Other recent insider transactions involving Regeneron Pharmaceuticals Inc (REGN) include a net sale of 10,814 shares made by Marion Mccourt , a net sale of 1,400 shares made by Arthur F Ryan , and a net sale of 7,918 shares made by Bonnie L Bassler .
In summary, during the past 3 months, insiders sold 26,837 shares of Regeneron Pharmaceuticals Inc (REGN) in total and bought 0 shares, with a net sale of 26,837 shares. During the past 18 months, 315,919 shares of Regeneron Pharmaceuticals Inc (REGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 315,919 shares.
Regeneron Pharmaceuticals Inc (REGN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Regeneron Pharmaceuticals Inc Insider Transactions
Charles A Baker Mailing Address
Above is the net worth, insider trading, and ownership report for Charles A Baker. You might contact Charles A Baker via mailing address: 777 Old Saw Mill River Road, Tarrytown Ny 10591.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
